Amgen's Repatha cuts death risk by 20% in heart study (AMGN:NASDAQ)
· seekingalpha.com
Amgen’s Phase 3 VESALIUS-CV data show Repatha cut death risk 20% in high-risk adults on statins—see ESC 2026 findings and key takeaways.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...